Cost-utility analysis of a structured medication review compared to usual care in Parkinson’s disease

Oonk, Nicol G.M.; Dorresteijn, Lucille D.A.; Berg, A D van den; Palen, Job van der; Movig, Kris L. L.; Nijmeijer, Henk-Willem; Kesteren, Mirjam E. van; Koffijberg, Hendrik

doi:10.1007/s00228-022-03438-4

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 In our quantitative Medication Review in PD study, executed in accordance with the Dutch Medication Review guidelines at that time, we found no improvement in quality of life in PD patients after an SMR and higher expenditure of health care costs compared to usual care. 9 , 12 , 33 The explanation for these outcomes seems multifactorial. The merely mild disease severity, the primary care setting, the difficult multidisciplinary communication lines, patient characteristics or any combination might play a role.…”

Section: Discussionmentioning

confidence: 99%

Structured medication reviews in Parkinson’s disease: pharmacists’ views, experiences and needs – a qualitative study

Oonk,

Dorresteijn,

te Braake

et al. 2024

Therapeutic Advances in Drug Safety

Self Cite

View full text Add to dashboard Cite

Background: Executing structured medication reviews (SMRs) in primary care to optimize drug treatment is considered standard care of community pharmacists in the Netherlands. Patients with Parkinson’s disease (PD) often face complex drug regimens for their symptomatic treatment and might, therefore, benefit from an SMR. However, previously, no effect of an SMR on quality of life in PD was found. In trying to improve the case management of PD, it is interesting to understand if and to what extent SMRs in PD patients are of added value in the pharmacist’s opinion and what are assumed facilitating and hindering factors. Objectives: To analyse the process of executing SMRs in PD patients from a community pharmacist’s point of view. Design: A cross-sectional, qualitative study was performed, consisting of face-to-face semi-structured in-depth interviews. Methods: The interviews were conducted with community pharmacists who executed at least one SMR in PD, till data saturation was reached. Interviews were transcribed verbatim, coded and analysed thematically using an iterative approach. Results: Thirteen pharmacists were interviewed. SMRs in PD were considered of added value, especially regarding patient contact and bonding, individualized care and its possible effect in the future, although PD treatment is found already well monitored in secondary care. Major constraints were time, logistics and collaboration with medical specialists. Conclusion: Although community pharmacist-led SMRs are time-consuming and sometimes logistically challenging, they are of added value in primary care in general, and also in PD, of which treatment occurs mainly in secondary care. It emphasizes the pharmacist’s role in PD treatment and might tackle future drug-related issues. Improvements concern multidisciplinary collaboration for optimized SMR execution and results.

show abstract

Section: Discussionmentioning

confidence: 99%

Structured medication reviews in Parkinson’s disease: pharmacists’ views, experiences and needs – a qualitative study

Oonk,

Dorresteijn,

te Braake

et al. 2024

Therapeutic Advances in Drug Safety

Self Cite

View full text Add to dashboard Cite

show abstract

Systematic literature review of the impact of psychiatric pharmacists

Ho,

Roberts,

Payne

et al. 2024

Mental Health Clinician

View full text Add to dashboard Cite

Introduction Pharmacists focusing on psychotropic medication management and practicing across a wide variety of healthcare settings have significantly improved patient-level outcomes. The Systematic Literature Review Committee of the American Association of Psychiatric Pharmacists was tasked with compiling a comprehensive database of primary literature highlighting the impact of psychiatric pharmacists on patient-level outcomes. Methods A systematic search of literature published from January 1, 1961, to December 31, 2022, was conducted using PubMed and search terms based on a prior American Association of Psychiatric Pharmacists literature review. Publications describing patient-level outcome results associated with pharmacist provision of care in psychiatric/neurologic settings and/or in relation to psychotropic medications were included. The search excluded articles for which there was no pharmacist intervention, no psychiatric disorder treatment, no clinical outcomes, no original research, no access to full text, and/or no English-language version. Results A total of 4270 articles were reviewed via PubMed, with 4072 articles excluded based on title, abstract, and/or full text in the initial pass and 208 articles selected for inclusion. A secondary full-text review excluded 11 additional articles, and 5 excluded articles were ultimately included based on a secondary review, for a final total of 202 articles meeting the inclusion criteria. A comprehensive database of these articles was compiled, including details on their study designs and outcomes. Discussion The articles included in the final database had a wide range of heterogeneity. While the overall impact of psychiatric pharmacists was positive, the study variability highlights the need for future publications to have more consistent, standardized outcomes with stronger study designs.

show abstract

Cost-utility analysis of a structured medication review compared to usual care in Parkinson’s disease

Cited by 2 publications

References 38 publications

Structured medication reviews in Parkinson’s disease: pharmacists’ views, experiences and needs – a qualitative study

Structured medication reviews in Parkinson’s disease: pharmacists’ views, experiences and needs – a qualitative study

Systematic literature review of the impact of psychiatric pharmacists

Contact Info

Product

Resources

About